Article Information
History
- March 25, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Lamprini Veneti, (Msc)1,#,
- Jacob Dag Berild, (MD)2,
- Sara Viksmoen Watle, (MD)2,
- Jostein Starrfelt, (PhD)1,
- Margrethe Greve-Isdahl, (MD)2,
- Petter Langlete, (PhD)1,
- Håkon Bøås, (PhD)2,
- Karoline Bragstad, (PhD)3,
- Olav Hungnes, (PhD)3 and
- Hinta Meijerink, (PhD)2
- 1Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
- 2Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
- 3Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
- ↵#Corresponding author: Lamprini Veneti, Department of Infection Control and Preparedness, Norwegian Institute of Public Health*, Postboks 222 Skøyen, 0213 Oslo, Norway, lamprini.veneti{at}fhi.no, +47 21078431
Posted March 25, 2022.
Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022
